RT journal article
T1 Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE Registry.
A1 Soto Cardenas, Maria Jose
A1 Ruiz Sada, Pablo
A1 López Núñez, Juan J.
A1 Samperiz, Angel
A1 Soto Cardenas, María José
A1 Pedrajas Navas, Jose Maria
A1 Porras, José Antonio
A1 Peris, María Luisa
A1 Debourdeau, Philippe
A1 Pace, Federica
A1 Monreal, Manuel
A2 Medicina
K1 autoimmune disorders
K1 venous thromboembolism
K1 bleeding
K1 recurrences
K1 anticoagulant therapy
AB Patients with autoimmune disorders are at an increased risk of venous thromboembolism (VTE), but this association has not beenconsistently evaluated. We used the RIETE (Registro Informatizado Enfermedad Trombo Embo ́ lica) database to compare therates of VTE recurrences, major bleeding, and death during the course of anticoagulation, according to the presence or absence ofautoimmune disorders. Of 71 625 patients with VTE recruited in February 2018, 1800 (2.5%) had autoimmune disorders. Medianduration of anticoagulant therapy was slightly longer in patients with autoimmune disorders (median, 190 vs 182 days; P ¼ .001).On multivariable analysis, patients with autoimmune disorders had a similar risk of VTE recurrences (hazard ratio [HR]: 0.93; 95%confidence interval [CI]: 0.68-1.27) or major bleeding (HR: 1.07; 95% CI: 0.82-1.40) and a lower risk to die (HR: 0.66; 95% CI:0.54-0.81) than those without autoimmune disorders. Patients with giant cell arteritis had the highest rates of major bleeding (8.6events per 100 patient-years) and the lowest rate of recurrences (zero). In other subgroups, the rates of both events were morebalanced. During anticoagulation, patients with or without autoimmune disorders had similar rates of VTE recurrences or majorbleeding. However, there were some differences between subgroups of patients with autoimmune disorders.
PB Sage
YR 2020
FD 2020
LK http://hdl.handle.net/10498/35251
UL http://hdl.handle.net/10498/35251
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 15-nov-2026